JESSICA ZARZYCKI: Open Payments
NPI 1245748375 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,227 in 56 payments from 13 companies in 2025. Trend: 2023 $501 · 2024 $900 · 2025 $1,227
Food & beverage: $1,148Education: $79
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $360 |
| ABBVIE INC. | 15 | $252 |
| Janssen Biotech, Inc. | 7 | $232 |
| Intercept Pharmaceuticals, Inc. | 3 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Lilly USA, LLC | 3 | $65 |
| PFIZER INC. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Celltrion USA Inc. | 1 | $22 |
Products named: XIFAXAN, TREMFYA, RINVOQ, OCALIVA, LINZESS, MAVYRET, OMVOH, DUPIXENT.
Industry payments across PA — which companies pay providers there.
